The Reitox network: frequently asked questions


This information brochure has been produced by the EMCDDA to provide answers to the most commonly asked questions on the Reitox network of national focal points and more broadly on national drugs observatories. Compiled over several years, it is a reference tool for both EU Member States and countries further afield on the network, its members, its role and development.

Download as PDF

Table of contents

  1. What is Reitox?
  2. Who are the members of the Reitox network?
  3. What is the Reitox network’s main mission?
  4. What are the Reitox network’s main strategic objectives?
  5. What is a national focal point and is there a difference with a national drugs observatory?
  6. What are the functions of Reitox national focal points at European level?
  7. What are the functions of Reitox national focal points at national level?
  8. How is Reitox managed?
  9. How should a national focal point be structured?
  10. What types of information should Reitox members provide to the EMCDDA and when?
  11. How many staff members should work in a national focal point and what qualifications do they need?
  12. How are Reitox national focal points financed?
  13. What is a ‘Reitox Academy’?
  14. Who can benefit from Reitox national focal points’ expertise at national level and how?
  15. What is the added value in joining the Reitox network for non‐EU countries?
  16. How can my country join the Reitox network or cooperate with it?
  17. Where can I find the contact details of Reitox members?